Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)

Recruiting

Phase 2

DoravirineDoravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)

Sponsor:

Merck Sharp & Dohme LLC

Code:

NCT04375800

Conditions

Human Immunodeficiency Virus (HIV) Infection

Eligibility Criteria

Sex: All

Age: 0 - 11

Healthy Volunteers: Not accepted

Interventions

Doravirine

2 NRTIs

DOR/3TC/TDF

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-03-03. This information was provided to ClinicalTrials.gov by Merck Sharp & Dohme LLC on 2026-02-24.